Skip to content

DZHK TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies

TranslatiOnal Registry for CardiomyopatHies (TORCH) - Plus as Part of the German Centre for Cardiovascular Research (DZHK)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04265040
Acronym
TORCH-Plus
Enrollment
2040
Registered
2020-02-11
Start date
2020-08-18
Completion date
2027-12-31
Last updated
2023-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyloidosis, Arrhythmogenic Right Ventricular Cardiomyopathy, DCM - Dilated Cardiomyopathy, HCM - Hypertrophic Cardiomyopathy, HOCM - Hypertrophic Obstructive Cardiomyopathy, Inflammatory Cardiomyopathy, Left Ventricular Noncompaction Cardiomyopathy, Non-ischemic Cardiomyopathy

Keywords

Cardiomyopathies, registry, data, biomaterial, genetics

Brief summary

The DZHK TranslatiOnal Registry for CardiomyopatHies (DZHK TORCH) represents a unique resource of clinical data and high quality biological samples to enable innovative clinical and molecular studies on cardiomyopathies (CMP). As a multi-center German cardiomyopathy registry, TORCH has been prospectively admitting patients since December 2014. 2,300 patients were recruited as planned. Taken together, patient data showed that the prevalence of these diseases is much higher in men than in women, atrial fibrillation is common in all forms of CMPs as well as rare forms of disease indicate a higher risk and higher morbidity. This DZHK TORCH register is now to be expanded with a second phase (DZHK TORCH-Plus). The second phase DZHK TORCH-Plus consists of 4 main modules: 1. Clinical phenotyping, follow-up & biosampling 2. Genomics, 3. Inflammation and 4. Biomarker. The central aims are 1) to significantly increase the number of probands (n = 4340) in order to better address the different types of CMPs, especially patients with rare CMP forms such as LVNC and ARVC or with probably molecularly explainable cardiomyopathies (familial DCM), 2) to prolong the longitudinal with a further follow-up to achieve sufficient events and thereby derive clinical recommendations for risk assessment, 3) to increase the number of probands with state-of-the-art phenotyping, 4) to pinpoint the effect of myocardial inflammation, fibrosis, gender and to determine or predict genotypes based for outcome, 5) to validate novel biomarkers developed in other DZHK studies, and 6) to foster active cooperation with international CMP registries and partners from industry.

Interventions

None listed

Sponsors

University Medicine Greifswald
CollaboratorOTHER
Charite University, Berlin, Germany
CollaboratorOTHER
German Heart Center
CollaboratorOTHER
University of Mannheim
CollaboratorOTHER
University Hospital Schleswig-Holstein
CollaboratorOTHER
Medical University of Hannover
CollaboratorOTHER
Goethe University
CollaboratorOTHER
Universitätsklinikum Hamburg-Eppendorf
CollaboratorOTHER
University Medical Center Mainz
CollaboratorOTHER
University Medical Center Goettingen
CollaboratorOTHER
Deutsches Herzzentrum Muenchen
CollaboratorOTHER
Technical University of Munich
CollaboratorOTHER
University Hospital Munich
CollaboratorOTHER
Kerckhoff Klinik
CollaboratorOTHER
University Hospital Heidelberg
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Non-ischemic structural cardiomyopathies * Age ≥ 18 or ≤ 80 years * The patient is able to understand the declaration of consent and to sign it dated * At least one of the following diagnoses depending on the specific TORCH- Plus inclusion / exclusion - SOP: Dilated Cardiomyopathy (DCM) * family / genetic * inflammatory / persistent myocarditis * idiopathic (after exclusion secondary cause) * left sided systolic dysfunction (EF ≤ 45%) Left ventricular hypertrophy * sarcomere hypertrophic cardiomoypathia (HCM, HOCM) * amyloid (AL: light chains, TTR: transthyretin, wild type) Left ventricular non-compaction cardiomyopathy (LVNC) Arrhythmogenic right ventricular cardiomyopathy (ARVC / D)

Exclusion criteria

The following

Design outcomes

Primary

MeasureTime frame
all-cause mortality4 years

Countries

Germany

Contacts

Primary ContactFarbod Sedaghat-Hamendani, Dr.
Farbod.Sedaghat-Hamedani@med.uni-heidelberg.de+496221/56-8676
Backup ContactJohannes Trebing, Dr.
Johannes.Trebing@med.uni-heidelberg.de

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 31, 2026